FDA Alerts
FDA Alerts
08/31/2016
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
08/31/2016
FDA Alerts
FDA Alerts
08/31/2016
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
08/31/2016
FDA Alerts
FDA Alerts
08/31/2016
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
08/31/2016
FDA Alerts
FDA Alerts
08/30/2016
The FDA has approved Afluria Quadrivalent for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.
08/30/2016
FDA Alerts
FDA Alerts
08/30/2016
The FDA has approved Afluria Quadrivalent for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.
08/30/2016
FDA Alerts
FDA Alerts
08/30/2016
The FDA has approved Afluria Quadrivalent for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.
08/30/2016
Infectious Diseases
Infectious Diseases
08/29/2016
The FDA has issued a revision to their February 2016 guidance for the screening of whole blood and blood components for Zika virus.
08/29/2016
Infectious Diseases
Infectious Diseases
08/29/2016
The FDA has issued a revision to their February 2016 guidance for the screening of whole blood and blood components for Zika virus.
08/29/2016
Infectious Diseases
Infectious Diseases
08/29/2016
The FDA has issued a revision to their February 2016 guidance for the screening of whole blood and blood components for Zika virus.
08/29/2016
FDA
FDA
08/01/2016
The approval was based on results from a randomized, double-blind, prospective Phase 3 study of 235 pediatric patients.
08/01/2016